A3P Biomedical strengthens the management team for international expansion
January 10, 2021
STOCKHOLM, January 10, 2021. A3P Biomedical strengthens the management team with Marianne Waplan as CFO, Marcela Björn as Director of Marketing & Sales and Malin Gidlund as Head of Lab Operations preparing for the company’s international expansion.
“In order to realize A3P Biomedical’s growth opportunities, we are building a strong organization. I am very proud that Marianne, Marcela and Malin – all with solid experience in their fields – have chosen to join us. We share the vision that Stockholm3 has the potential to revolutionize early detection of prostate cancer. We also share the ambition to build a new exciting company based on world-leading technology that attracts competent employees. Several key people are now in place and we intend to further strengthen the organization during the year.” Martin Steinberg, CEO of A3P Biomedical.
Marianne Waplan, CFO has extensive experience as CFO and management of finance functions. She contributed to the work of listing Hoist Finance on the stock exchange, has been accounting manager at Nordea and SEB and most recently as interim CFO at the private equity company Trill Impact.
Marcela Björn, Director Marketing & Sales has more than 20 years of experience in sales and marketing globally, including as Sales Director for EMEA/Latin America for Vitrolife and management roles within B. Braun Group and Terumo.
Malin Gidlund, Head of Lab Operations, has more than 20 years of experience in Life Science. She most recently came from the role as head of drug development at Orexo and has previously worked with product and process development within Recipharm and AstraZeneca.
About A3P Biomedical
A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P’s main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com
About Stockholm3
Stockholm3 is a blood-based test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.
Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care, as a reflex test to PSA at values 1.5-20 ng/ml. Benefits include the ability to reduce unnecessary MRIs, benign and Grade Group 1 prostate biopsies for men with elevated PSA, while simultaneously improving detection of clinically significant cancers in men with low or normal PSA values. Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 40-90% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 40-50% compared to PSA.
Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about our clinical studies please visit www.a3p.com.
About prostate cancer
Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.
Press contact:
Cecilia Edström
cecilia.edstrom@a3p.com
+46 72 226 2328